Podimetrics, a health tech startup founded in 2011, is revolutionizing diabetes care with its SmartMat™, designed to prevent diabetic foot complications. The company's innovative offering, coupled with integrated clinical and patient support services, has attracted significant attention and investment. Recently, on 22 November 2022, Podimetrics secured a substantial $25.00M Debt Financing investment from CIBC Innovation Banking. This injection of funds validates the confidence that notable investors, including Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health, have placed in the company. Podimetrics' success lies in its ability to engage high-risk patients effectively, while enabling clinicians to achieve unparalleled outcomes, ultimately reducing healthcare costs. Operating in the United States, with headquarters in Somerville, M.A., Podimetrics continues to make strides in the Health Care and Medical Devices industries. For more information, visit podimetrics.com or follow them on Twitter @podimetrics.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Debt Financing | $25.00M | 1 | 22 Nov 2022 | |
Series C | $45.00M | 5 | Medtech Convergence Fund | 24 Mar 2022 |
Series B | $8.00M | 4 | 19 Aug 2020 | |
Series B | $3.15M | 1 | 10 Dec 2019 | |
Series B | $13.40M | 4 | 09 May 2019 |
No recent news or press coverage available for Podimetrics.